Aligos Therapeutics Business Summary

Aligos Therapeutics, Inc. (ALGS) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic research collaborations—most notably with Merck and Xiamen Amoytop Biotech—and federal R&D grants from the NIH/NIAID. The company’s primary business segments are dedicated to developing "best-in-class" oral small molecule and oligonucleotide therapeutics for Chronic Hepatitis B (CHB), Metabolic Dysfunction-Associated Steatohepatitis (MASH), and viral pathogens including coronaviruses. Its clinical pipeline is anchored by pevifoscorvir sodium, a capsid assembly modulator in Phase 2 trials, and ALG-055009, a THR-β agonist targeting liver fat reduction. Aligos operates within a competitive landscape alongside firms such as Nimbus Therapeutics, NGM Biopharmaceuticals, and NorthSea Therapeutics, positioning itself as a specialized innovator focused on achieving functional cures for liver diseases by simultaneously targeting viral replication, integration, and reservoir maintenance. The leadership team is led by Co-founder, President, and CEO Dr. Lawrence M. Blatt, a veteran virologist who previously founded Alios BioPharma (acquired by Johnson & Johnson for $1.75 billion) and held senior roles at Gilead Sciences and InterMune. The executive suite was bolstered in January 2026 by the appointment of James Hassard as EVP and Chief Commercial Officer, who brings extensive product launch experience from Arrowhead Pharmaceuticals and Crinetics. Other key leaders include Chief Scientific Officer Julian Symons, formerly of Alios and Roche, and Chief Financial Officer Lesley Ann Calhoun. The company’s board and investor base feature significant industry pedigree, including independent directors Heather Preston (Senior Advisor to TPG Biotech) and Margarita Chavez (Venture Partner at Wellington Partners), with major institutional backing from Wellington Management, Alyeska Investment Group, and Adage Capital Partners.